Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5689223 | European Urology | 2017 | 4 Pages |
Abstract
This analysis showed limited clinical benefit for subsequent abiraterone acetate plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer following initial treatment with abiraterone acetate plus prednisone. This analysis does not support prioritization of subsequent abiraterone acetate plus prednisone or enzalutamide following initial therapy with abiraterone acetate plus prednisone.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Matthew R. Smith, Fred Saad, Dana E. Rathkopf, Peter F.A. Mulders, Johann S. de Bono, Eric J. Small, Neal D. Shore, Karim Fizazi, Thian Kheoh, Jinhui Li, Peter De Porre, Mary B. Todd, Margaret K. Yu, Charles J. Ryan,